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Anatomic Burden OutPerforms Ischemic Burden
From “COURAGE” to “ISCHEMIA”
Suraj Dahal, MD and Matthew J. Budoff, MD
Treatment of stable ischemic heart disease remains controversial due to lack
of proper measures to identify the vulnerable patient who will suffer acute
coronary  events.  Imaging  modalities  can  identify  rupture-prone  coronary
plaques but studies have found that most plaque ruptures without causing
clinical events  (1). High risk plaques identified by CT Angiogram (CTA) was
found to be predictive of acute coronary events (ACS) in a large cohort study
but  the  extent  of  atherosclerotic  burden  was  a  confounder  (2).  As  such,
numerous studies have suggested total atherosclerotic plaque burden as the
main  determinant  of  adverse  patient  outcomes  (3,4).  Coronary  artery
calcium  (CAC)  is  a  highly  specific  surrogate  for  coronary  atherosclerosis
burden  and  is  the  most  predictive  single  cardiovascular  risk  marker  in
asymptomatic persons  (5). The greater the atherosclerotic  plaque burden,
the more likely plaque ruptures will  occur and the greater the probability
that one of them triggers vascular thrombosis and a clinical event (6). 
For many decades, inducible  myocardial ischemia detected by myocardial
perfusion stress testing has been used to guide therapy;  however,  it  has
been shown to be imperfect to predict significant stenosis in the coronary
tree  at  time  of  angiography.  Inducible  ischemia  happens  due  to  supply-
demand  mismatch,  and  due  to  its  chronicity,  it  allows  myocardial
preconditioning  and  cellular  adaptations,  which  reduce  the  risk  of  acute
myocardial  infarction  and  ventricular  arrhythmia.  The  idea  that
revascularization benefits patients with high ischemic burden stem from an
observational study by Hachamovitch et al.(7) in 2003 which showed as the
amount of  inducible  ischemia increases,  there is  more survival  benefit  in
patients with revascularization compared to medical therapy. As COURAGE
(Clinical  Outcomes  Utilizing  Revascularization  and  Aggressive  Drug
Evaluation) (8) trial failed to show benefits of revascularization over optimal
medical therapy (OMT)in stable CAD patients.  One possible explanation was
that among 60% of patients enrolled in COURAGE trial after nuclear stress
imaging,  most  had  less  than  moderate  ischemia  (i.e.  <  10%  ischemic
myocardium)  and  this  factor  was  suggested  to  have  contributed  to  the
overall neutral results of the trial (9). 
What would be the results of the COURAGE trial if most of the patients
had  moderate  to  severe  ischemia  instead  of  mild  ischemia?  A  subgroup
analysis from the COURAGE trial reported no reduction in death or MI among
patients  with  moderate  to  severe  ischemia  compared with  mild  ischemia
(10). Another substudy from the COURAGE trial looked at 314 patients with
baseline and follow up nuclear stress test and showed that revascularization
with OMT resulted in greater reduction in ischemic burden compared with
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OMT alone  (11). Similarly, a nuclear substudy of the BARI 2D (Randomized
trial  of  Therapies  for  Type  II  Diabetes  and  CAD)  trial  suggested  left
ventricular  ejection  fraction  (LVEF),  but  not  the  percent  of  ischemic
myocardium,  predicted  event  rates  (12).  A  subgroup  of  STITCH  (Surgical
Treatment  for  Ischemic  Heart  Disease)  trial  further  indicated  that  the
presence of inducible ischemia on stress testing in patients with CAD and
severe left  ventricular  dysfunction is  not  associated with worse prognosis
and does not identify those with greater therapeutic benefit from surgical
revascularization  (13).  Finally, Mancini et al.(14) showed in COURAGE trial
that when both anatomic burden and ischemic burden of disease at baseline
were considered concomitantly, anatomic burden was a consistent predictor
of death, MI, and non-ST elevation MI,  whereas ischemic burden was not.
Also, the 5-year results of the SCOT-HEART (Scottish Computed Tomography
of the Heart) study suggested that anatomic testing (CTA) lowers the rate of
death or non-fatal MI by 41% greater than traditional stress testing (15).
The failure of the COURAGE and the BARI 2D trials suggested a need for 
another large randomized trial, but at this time, to enroll more high-risk 
patients to get better revascularization results with percutaneous coronary 
intervention (PCI). Once again, functional testing, but now with moderate to 
severe ischemia, was chosen as a measure to select high-risk patients. This 
algorithm was incorporated in the ISCHEMIA (International Study of 
Comparative Health Effectiveness with Medical and Invasive Approaches)
(16) trial where 5179 patients with at least moderate ischemia (i.e. >10% 
ischemic myocardium) were randomized to PCI plus OMT or OMT alone. The 
large sample size was thought to overcome any sample size limitations in 
the previous subgroup analysis. The ISCHEMIA trial failed to show any 
difference in outcomes from PCI plus OMT compared to OMT alone. However,
when stratifying for outcomes by severity of ischemia and anatomy (17), a 
strong association was found between extent and severity of CAD and risk of 
death and MI. There was no association between ischemia severity and 
death. The 4-year all-cause mortality event rate in patients with 3-vessel 
disease, 2-vessel disease, and 1-vessel disease (all detected by CTA) were 
7%, 5.3%, and 2% respectively (p<0.001). The mortality rate in the severely 
ischemic group, moderately ischemic group, and mildly ischemic group 
(detected by stress tests) were 5.8 %, 6.6%, and 9.1% respectively 
(worsening outcomes with more mild ischemia). The authors concluded that 
anatomy (by CTA) was more predictive of outcomes than ischemia, and there
was a very strong association between extent and severity of atherosclerosis
and risk of death and MI. 
The sum of currently available literature suggests that the severity of 
ischemia based on stress testing does not identify high-risk patients. If it 
does so as in some observational studies, then it is because patients with 
high ischemic burden are likely to also have high anatomic burden which can
indeed trigger vascular thrombosis. Perhaps an algorithm of CTA first, then 
lesion specific ischemia (such as selective use of FFR ( Fractional Flow 
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Reserve) or FFRCT) to target lesion-specific ischemia would fare better against
OMT alone (18). 
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